Mutual of America Capital Management LLC Sells 952 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Mutual of America Capital Management LLC decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.0% during the 2nd quarter, Holdings Channel reports. The firm owned 23,030 shares of the medical research company’s stock after selling 952 shares during the period. Mutual of America Capital Management LLC’s holdings in IQVIA were worth $4,869,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in IQV. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in shares of IQVIA by 339.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after purchasing an additional 1,597,003 shares during the last quarter. Morningstar Investment Services LLC grew its holdings in shares of IQVIA by 96.9% in the fourth quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock worth $286,704,000 after purchasing an additional 606,333 shares during the last quarter. Capital Research Global Investors boosted its holdings in IQVIA by 42.2% in the fourth quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock valued at $461,675,000 after acquiring an additional 592,372 shares in the last quarter. Renaissance Technologies LLC bought a new stake in IQVIA in the second quarter valued at $70,610,000. Finally, Cadian Capital Management LP bought a new stake in IQVIA in the fourth quarter valued at $70,108,000. Institutional investors own 89.62% of the company’s stock.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is owned by insiders.

IQVIA Price Performance

IQV opened at $242.12 on Friday. The stock has a 50-day moving average price of $240.60 and a 200-day moving average price of $234.07. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The firm has a market cap of $44.14 billion, a PE ratio of 33.08, a P/E/G ratio of 2.25 and a beta of 1.49. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last issued its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. During the same quarter in the previous year, the firm earned $2.22 EPS. IQVIA’s revenue was up 2.3% on a year-over-year basis. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IQV. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and cut their price target for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. Argus raised IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Royal Bank of Canada assumed coverage on IQVIA in a research report on Wednesday, September 4th. They set an “outperform” rating and a $275.00 price objective for the company. Robert W. Baird raised their price objective on IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research report on Friday. Finally, UBS Group raised their price objective on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $267.00.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.